Pharmacokinetics and Comparative Bioavailability of Nicotine From Two Variants of NP2, NP2-4mg and NP2-6mg, Compared to Nicotine Lozenge 4mg (Loz-4mg) and Nicotine Gum 4mg (Gum-4mg)
NCT ID: NCT06171490
Last Updated: 2024-08-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
56 participants
INTERVENTIONAL
2023-10-20
2024-03-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Assess PK, PD, Nicotine Extraction, Palatability, Subjective Effects of Nicotine Pouches - Daily Nicotine Users
NCT06170138
Single-dose Pharmacokinetics of Oral Nicotine Replacement Products
NCT01228617
Single-dose Nicotine Pharmacokinetics With Four Oral Nicotine Replacement Products
NCT01234896
Pilot Pharmacokinetic Study of Investigational Sublingual Nicotine Tablet Versus COMMIT Nicotine Lozenge
NCT01887847
Comparative Pharmacokinetic Study of New Oral Nicotine Replacement Therapy Products.
NCT01227720
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Product Sequence 1
From Day 1 to Day 4, after at least 23 hours of abstinence from any nicotine/tobacco containing products, subjects will use one of the four investigational products according to randomized product use sequence and as instructed by the investigational site personnel.
The list of possible sequences are:
NP2-4mg; NP2-6mg; Loz-4mg; Gum-4mg / NP2-6mg; Gum-4mg; NP2-4mg; Loz-4mg / Gum-4mg; Loz-4mg; NP2-6mg; NP2-4mg / Loz-4mg; NP2-4mg; Gum-4mg; NP2-6mg
NP2-4mg
NP2-4 mg is a new product containing tobacco-derived nicotine.
NP2-6 mg
NP2-6 mg is a new product containing tobacco-derived nicotine.
Loz-4mg
The Loz-4mg reference product is a commercially available 4mg nicotine lozenge.
Gum-4mg
The Gum-4mg reference product is a commercially available 4mg nicotine gum.
Product Sequence 2
From Day 1 to Day 4, after at least 23 hours of abstinence from any nicotine/tobacco containing products, subjects will use one of the four investigational products according to randomized product use sequence and as instructed by the investigational site personnel.
The list of possible sequences are:
NP2-4mg; NP2-6mg; Loz-4mg; Gum-4mg / NP2-6mg; Gum-4mg; NP2-4mg; Loz-4mg / Gum-4mg; Loz-4mg; NP2-6mg; NP2-4mg / Loz-4mg; NP2-4mg; Gum-4mg; NP2-6mg
NP2-4mg
NP2-4 mg is a new product containing tobacco-derived nicotine.
NP2-6 mg
NP2-6 mg is a new product containing tobacco-derived nicotine.
Loz-4mg
The Loz-4mg reference product is a commercially available 4mg nicotine lozenge.
Gum-4mg
The Gum-4mg reference product is a commercially available 4mg nicotine gum.
Product Sequence 3
From Day 1 to Day 4, after at least 23 hours of abstinence from any nicotine/tobacco containing products, subjects will use one of the four investigational products according to randomized product use sequence and as instructed by the investigational site personnel.
The list of possible sequences are:
NP2-4mg; NP2-6mg; Loz-4mg; Gum-4mg / NP2-6mg; Gum-4mg; NP2-4mg; Loz-4mg / Gum-4mg; Loz-4mg; NP2-6mg; NP2-4mg / Loz-4mg; NP2-4mg; Gum-4mg; NP2-6mg
NP2-4mg
NP2-4 mg is a new product containing tobacco-derived nicotine.
NP2-6 mg
NP2-6 mg is a new product containing tobacco-derived nicotine.
Loz-4mg
The Loz-4mg reference product is a commercially available 4mg nicotine lozenge.
Gum-4mg
The Gum-4mg reference product is a commercially available 4mg nicotine gum.
Product Sequence 4
From Day 1 to Day 4, after at least 23 hours of abstinence from any nicotine/tobacco containing products, subjects will use one of the four investigational products according to randomized product use sequence and as instructed by the investigational site personnel.
The list of possible sequences are:
NP2-4mg; NP2-6mg; Loz-4mg; Gum-4mg / NP2-6mg; Gum-4mg; NP2-4mg; Loz-4mg / Gum-4mg; Loz-4mg; NP2-6mg; NP2-4mg / Loz-4mg; NP2-4mg; Gum-4mg; NP2-6mg
NP2-4mg
NP2-4 mg is a new product containing tobacco-derived nicotine.
NP2-6 mg
NP2-6 mg is a new product containing tobacco-derived nicotine.
Loz-4mg
The Loz-4mg reference product is a commercially available 4mg nicotine lozenge.
Gum-4mg
The Gum-4mg reference product is a commercially available 4mg nicotine gum.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NP2-4mg
NP2-4 mg is a new product containing tobacco-derived nicotine.
NP2-6 mg
NP2-6 mg is a new product containing tobacco-derived nicotine.
Loz-4mg
The Loz-4mg reference product is a commercially available 4mg nicotine lozenge.
Gum-4mg
The Gum-4mg reference product is a commercially available 4mg nicotine gum.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has smoked on a daily basis for at least the last 18 months prior to the Screening visit.
* Subject has smoked on average ≥10 commercially available regular CIG/day over the last 4 weeks. Smoking status will be verified based on a urinary cotinine test (cotinine ≥200 ng/mL).
* Subject is healthy as judged by the Investigator based on available assessments from the screening period (e.g., safety laboratory, spirometry, vital signs, physical examination, ECG, and medical history).
Exclusion Criteria
* Subject is legally incompetent, or physically or mentally incapable of giving consent (e.g., emergency situation, under guardianship, prisoners).
* Subject has a clinically relevant disease which requires medication or any other medical condition including abnormal spirometry, safety laboratory, as determined by the Investigator.
* Subject presents difficulty with venipuncture and/or poor venous access.
* Subject has an oromucosal or dental condition, which may affect the use of the investigational products, as determined by the Investigator or subject has orthodontic braces and retention wire (could likely interfere with the gum dosing).
* Subject has medical conditions which require, or will require during the study, a medical intervention (e.g., start of treatment, surgery, hospitalization).
* Presence of fever (body temperature \>37.5°C) (e.g., a fever associated with a symptomatic viral or bacterial infection) within 2 weeks prior to dosing.
* Subject has a Hemoglobin level \< 11.0 g/dL for females and \< 12.0 g/dL for males at the Screening.
* Subject uses medication or any substance that aids in smoking cessation.
* Subject postponed the decision to quit using tobaccoor nicotine-containing products in order to participate in this study.
* Subject previously attempted to quit using tobacco- or nicotine-containing products within 28 days prior to the first study product administration.
* Subject has donated plasma within seven days prior to Screening or has donated or lost 450 mL or more of whole blood within 8 weeks prior to Screening for males, and in the 12 weeks prior to Screening for females.
* Subject has a known sensitivity or allergy to any of the investigational products, or ingredients.
* Subject has a positive serology test for HIV 1/2, Hepatitis B, Hepatitis C.
* Subject has a history of alcohol abuse within one year prior to screening or regular use of alcohol within six months prior to screening that exceeds 10 units for women or 15 units for men of alcohol per week (1 unit = 340 mL of beer 5%, 140 mL of wine 12%, or 45 mL of distilled alcohol 40%).
* Subject has a positive urine drug test. Investigator will assess whether THC positive subjects are eligible for participation in the study.
* Subject has a positive alcohol breath test.
* Subject or one of their family members is a current or former employee of the tobacco industry.
* Subject or one of their family members a is an employee of the investigational site or of any other parties involved in the study.
* Subject has participated in another clinical study within 30 days prior to the Screening Visit or concomitantly participates in an investigational study involving no drug or device administration.
* Subject has been previously screened or enrolled in this study (except alternate subjects).
* For women only: subject is pregnant (does not have negative pregnancy tests at Screening Visit and at Admission) or is a lactating female.
* For women of childbearing potential only: subject does not agree to use an acceptable method of effective contraception.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Philip Morris Products S.A.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christelle Haziza, PhD
Role: STUDY_CHAIR
Philip Morris Products S.A.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pharma Medica Research Inc.
Toronto, Ontario, Canada
Syneos Health Clinique Inc.
Québec, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PZ-PK-03-CAN
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.